A Phase 2 Study of HX301 in Patients with High-grade Giloma
A phase 1/2 trial of Temozolomide in glioma & glioblastoma, run by Hangzhou Hanx Biopharmaceuticals, Ltd., now recruiting.
Overview
A Phase 2 Study of HX301 in Patients with High-grade Giloma is a phase 1/2 interventional study registered as NCT06703255 by Hangzhou Hanx Biopharmaceuticals, Ltd., with 72 participants planned, started 2025-01-08 and due to reach its primary completion in 2026-12-31. Interventions recorded: HX301+/Temozolomide.
Similar pages
not linked directly; found by shared links- TrialA Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialA Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialPh I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialJK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialSonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialGlioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialSafety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialA Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.